Impact of testosterone replacement therapy on myocardial infarction, stroke, and death in men with low testosterone concentrations in an integrated health care system

American Journal of Cardiology

Volumn 117, Issue 5, 2016, Pages 794-799

  Anderson, Jeffrey L ^a,b   May, Heidi T ^a   Lappé, Donald L ^a   Bair, Tami ^a   Le, Viet ^a   Carlquist, John F ^a,b   Muhlestein, Joseph B ^a,b  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE; BIOLOGICAL MARKER;

ADULT; AGED; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORRELATION ANALYSIS; DRUG SAFETY; FOLLOW UP; GROUPS BY AGE; HEART DEATH; HEART INFARCTION; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; BLOOD; CAUSE OF DEATH; DOSE RESPONSE; HORMONE SUBSTITUTION; HYPOGONADISM; INCIDENCE; MYOCARDIAL INFARCTION; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR; STROKE; SURVIVAL RATE; TIME FACTOR; TRENDS; UTAH;

BIOMARKERS; CAUSE OF DEATH; DELIVERY OF HEALTH CARE, INTEGRATED; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; SURVIVAL RATE; TESTOSTERONE; TIME FACTORS; UTAH;

EID: 84958864126     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.11.063     Document Type: Article

References (19)

1. FDA Joint Meeting for Bone, Reproductive and Urology Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSARM AC) 2014 Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/ucm380883.htm Accessed January 17, 2015
2. S.M. Harman, E.J. Metter, J.D. Tobin, J. Pearson, and M.R. Blackman Baltimore Longitudial Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudial Study of Aging J Clin Endocrinol Metab 86 2001 724 731
3. R. Sharma, O.A. Oni, K. Gupta, G. Chen, M. Sharma, B. Dawn, R. Sharma, D. Parashara, V.J. Savin, Ambrose, and R.S. Barua Normalization of testosterone of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men Eur Heart J 36 2015 2706 2715
4. K.T. Khaw, M. Dowsett, E. Folkerd, S. Bingham, N. Wareham, R. Luben, A. Welch, and N. Day Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study Circulation 116 2007 2694 2701
5. J. Baillargeon, R.J. Urban, K.J. Ottenbacher, K.S. Pierson, and J.S. Goodwin Trends in androgen prescribing in the United States, 2001 to 2011 JAMA Intern Med 173 2013 1465 1466
6. M.M. Shores, N.L. Smith, C.W. Forsberg, B.D. Anawalt, and A.M. Matsumoto Testosterone treatment and mortality in men with low testosterone levels J Clin Endocrinol Metab 97 2012 2050 2058
7. V. Muraleedharan, H. Marsh, D. Kapoor, K.S. Channer, and T.H. Jones Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes Eur J Endocrinol 169 2013 725 733
8. J. Baillargeon, R.J. Urban, Y.F. Kuo, K.J. Ottenbacher, M.A. Raji, F. Du, Y.L. Lin, and J.S. Goodwin Risk of myocardial infarction in older men receiving testosterone therapy Ann Pharmacother 48 2014 1138 1144
9. R. Vigen, C.I. O'Donnell, A.E. Baron, G.K. Grunwalk, T.M. Maddox, S.M. Bradley, A. Bargawi, G. Woning, M.E. Wierman, M.E. Plomondon, J.S. Rumsfeld, and P.M. Ho Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels JAMA 310 2013 1829 1836
10. W.D. Finkle, S. Greenland, G.K. Ridgeway, J.L. Adams, M.A. Frasco, M.B. Cook, J.F. Fraumeni Jr., and R.N. Hoover Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men PLoS One 29 2014 e85805
11. S. Basaria, A.D. Coviello, T.G. Travison, T.W. Storer, W.R. Farwell, A.M. Jette, R. Eder, S. Tennstedt, J. Ulloor, A. Zhang, K. Choong, K.M. Lakshman, N.A. Mazer, R. Miciek, J. Krasnoff, A. Elmi, P.E. Knapp, B. Brooks, E. Appleman, S. Aggarwal, G. Bhasin, L. Hede-Brierley, A. Bhatia, L. Collins, N. LeBrasseur, L.D. Fiore, and S. Bhasin Adverse events associated with testosterone administration N Engl J Med 363 2010 109 122
12. A. Morgentaler, M.M. Miner, M. Caliber, A.T. Guay, M. Khera, and A.M. Traish Testosterone therapy and cardiovascular risk: advances and controversies Mayo Clin Proc 90 2015 224 251
13. M.T. Gettman The impact of testosterone therapy in men on cardiovascular risk: don't be too quick to condemn Mayo Clin Proc 90 2015 163 165
14. Health Canada. Information Update - Possible cardiovascular problems associated with testosterone products. Epub 2014-11-21. Available at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/40587a-eng.php#you-vous. Accessed on January 17, 2015.
15. European Medicines Agency. Issue: EMA/706140. No consistent evidence of an increased risk of heart problems with testosterone medicines. Epub Date: 21 November 2014. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2014/11/news-detail-002218.jsp&mid=WC0b01ac058004d5c1. Accessed on January 17, 2015.
16. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
17. B.D. Horne, H.T. May, J.B. Muhlestein, B.S. Ronnow, D.L. Lappe, D.G. Renlund, A.G. Kfoury, J.F. Carlquist, P.W. Fisher, R.R. Pearson, T.L. Bair, and J.L. Anderson Exceptional mortality prediction by risk scores from common laboratory tests Am J Med 122 2009 550 558
18. US Food and Drug Administration. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. Epub March 3, 2015. Available at: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm436280.htm. Accessed on March 6, 2015.
19. R. Srinath, S. Hill Golden, K.A. Carson, and A. Dobs Endogenous testosterone and its relationship to preclinical and clinical measures of cardiovascular disease in the atherosclerosis risk in communities (ARIC) study J Clin Endocrinol Metab 100 2015 1602 1608